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Abstract
Background: Amyloid b (Ab), a causative peptide of Alzheimer’s disease, is generated by intracellular metabolism of amyloid
b-protein precursor (APP). In general, mature APP (mAPP, N- and O-glycosylated form) is subject to successive cleavages by
a-o rb-, and c-secretases in the late protein secretory pathway and/or at plasma membrane, while immature APP (imAPP, N-
glycosylated form) locates in the early secretory pathway such as endoplasmic reticulum or cis-Golgi, in which imAPP is not
subject to metabolic cleavages. X11-like (X11L) is a neural adaptor protein composed of a phosphotyrosine-binding (PTB)
and two C-terminal PDZ domains. X11L suppresses amyloidogenic cleavage of mAPP by direct binding of X11L through its
PTB domain, thereby generation of Ab lowers. X11L expresses another function in the regulation of intracellular APP
trafficking.
Methodology: In order to analyze novel function of X11L in intracellular trafficking of APP, we performed a functional
dissection of X11L. Using cells expressing various domain-deleted X11L mutants, intracellular APP trafficking was examined
along with analysis of APP metabolism including maturation (O-glycosylation), processing and localization of APP.
Conclusions: X11L accumulates imAPP into the early secretory pathway by mediation of its C-terminal PDZ domains,
without being bound to imAPP directly. With this novel function, X11L suppresses overall APP metabolism and results in
further suppression of Ab generation. Interestingly some of the accumulated imAPP in the early secretory pathway are likely
to appear on plasma membrane by unidentified mechanism. Trafficking of imAPP to plasma membrane is observed in other
X11 family proteins, X11 and X11L2, but not in other APP-binding partners such as FE65 and JIP1. It is herein clear that
respective functional domains of X11L regulate APP metabolism at multiple steps in intracellular protein secretory
pathways.
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Introduction
X11 proteins (X11s) comprise a family of evolutionarily
conserved molecules, which include: X11/X11a/mint1, X11L/
X11b/mint2 and X11L2/X11c/mint3 in mammals [1], two
orthologous proteins in D. melanogaster [2,3], and one in C. elegans
[4]. X11s are composed of a relatively unique N-terminal half and
a conserved C-terminal half, which includes a phosphotyrosine
binding/phosphotyrosine interaction (PTB/PI) domain and two
PDZ domains. Through protein-protein interactions, mediated by
the PTB/PI and/or PDZ domains, X11s are thought to play
various important regulatory roles in synapse formation, protein
transport and protein metabolism [5].
In mammals, X11 and X11L are expressed predominantly in
the brain, while X11L2 is expressed ubiquitously [5]. The PTB/PI
domain of X11s binds to the cytoplasmic domain of Alzheimer’s
amyloid b-protein precursor (APP) and suppresses the intracellular
metabolism of APP [1,6–9]. APP is a type I membrane protein,
subject to N-glycosylation (immature APP/imAPP) in the endo-
plasmic reticulum (ER) in the early protein secretory pathway, and
further subject to O-glycosylation in the Golgi compartment in the
late secretory pathway [10]. Mature APP (mAPP), possessing both
N- and O-glycans, is subject to consecutive cleavages at the
extracellular juxtamembrane region by a-o rb-secretase, and at
the transmembrane region by c-secretase in the late secretory
pathway [11]. This amyloidogenic cleavage of mAPP by b- and c-
secretases generates neurotoxic amyloid b-protein (Ab), and the
generation and oligomer formation of Ab are widely believed to be
the primary cause of Alzheimer’s disease (AD) [12]. Other
substrates of c-secretase such as APP-like proteins and neurexin,
but not Notch, also bind to X11s, although the interaction is not
restricted to type I membrane proteins [5].
In transgenic mice, overexpressing X11 or X11L, together with
the human APP Swedish mutation, resulted in a decrease of
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mice overexpressing the human APP Swedish mutation alone
[13,14]. Conversely, the amyloidogenic metabolism of endogenous
APP and overexpressed human APP, including the generation of
Ab, was enhanced in the brains of X11-deficient, X11L-deficient
and X11/X11L doubly-deficient mice [15–17]. In the brain, X11s
are thought to associate with mAPP outside the detergent-resistant
membrane (DRM) or lipid raft, which is rich in active b-secretase
(BACE) [18]. It was also reported that dysfunctional X11s in X11s
knock-out mice facilitated the entry of mAPP into the DRM and
enhanced the cleavage of uncomplexed mAPP by BACE [16].
In addition to suppression of the amyloidogenic cleavage of
mAPP by direct binding between the PTB/PI domain of X11s and
the 681-GYENPTY-687 motif in the APP cytoplasmic region
[19,20], X11s show other regulations in APP metabolism. Indeed,
cells overexpressing X11s showed intracellular imAPP accumula-
tion, which means a suppression of APP maturation by
invalidation of O-glycosylation [1]. This resulted in a reduction
in the secretion of the N-terminal APP fragment, sAPPa/b; in the
generation of the C-terminal APP fragment, APP CTFa/b
(generated from the primary cleavage of APP by a-o rb-secretase);
and in the secretion of Ab, generated by the intramembranous c-
cleavage of CTFb [1,6,7]. Thus, the intracellular trafficking of
APP, including the APP maturation steps regulated by X11s, is
closely associated with APP metabolism [11,19].
In this study, we performed a functional dissection of X11L,
which revealed that: (1) the C-terminal PDZ domains of X11L
regulate the passage of APP into early secretory pathway without
the direct-binding to APP and consequently regulate overall APP
metabolism including Ab generation, and (2) the imAPP
accumulated in early secretory pathway is subject to transport to
plasma membrane by unidentified way.
Results
Identification of X11L domain involved in the
suppression of APP maturation
APP is cleaved by secretases during the late secretory pathway
after it has undergone glycosylation; thus, mAPP is indeed the
substrate of the secretases and Ab is generated from mAPP
[11,19]. Previous studies showed that overexpression of X11L
suppressed APP maturation and resulted in the accumulation of
imAPP in cells [1]. To identify the functional region of X11L
involved in the suppression of APP maturation, we prepared
various domain-deleted X11L mutants (Fig. 1A). N-terminal
EGFP-tagged X11L mutants were expressed in N2a cells with
FLAG-APP, and the maturation of APP was examined by
immunoblotting (Fig. 1B). The ability of X11L to suppress the
maturation of APP and to accumulate imAPP is indicated as the
relative ratio of imAPP to mAPP (imAPP/mAPP) (Fig. 1C)i n
which the ratio of cells with no X11L expression was set as 1.0
(column 2).
Moderate amounts of mAPP was detected along with imAPP in
cells in the absence of X11L expression (Fig. 1B, lane 2), while the
expression of X11L in these cells resulted in the suppression of
APP maturation and the significant accumulation of imAPP,
which also leads to a decrease in the levels of both CTFa and
CTFb, the products of mAPP cleavage by primary a-o rb-
secretase (compare lane 2 to lane 3; to indicate CTFb, a relative
darker exposure of film was shown in lower row of Fig. 1B).
In response to the expression of the X11L mutants, which
showed expression levels almost identical to that of wild-type
X11L (some mutants with smaller size, PTB+C, C and PTB, tend
to express in lower level slightly), PTB+C( Fig. 1B, lane 4; Fig. 1C,
column 4) and C (Fig. 1B, lane 10; Fig. 1C, column 10) produced
a significant accumulation of imAPP, accompanied with a
decrease in CTFa and CTFb (compare lanes 4 and 10 to lane 2
in the lower row of Fig. 1B). The data indicate that X11L
including the two PDZ domains, PTB+C (column 4), DPTB
(column 6), C (column 10), and F520V (column 12) mutants along
with entire X11L (column 3) showed a significant accumulation of
imAPP (Fig. 1C), suggesting that the two PDZ domains of X11L
are required for the suppression of APP maturation.
Because it has been widely accepted that X11s can regulate APP
metabolism by a direct binding to APP through its PTB domain
[1,6–9], we also verified whether the association of APP with
X11L is required for the accumulation of imAPP. It has already
been known that X11L lacking APP-binding PTB domain (DPTB;
lane 6 in Fig. 1B) and X11L possessing an amino acid substitution
at Phe520 (F520V; lane 12 in Fig. 1B) don’t interact with APP
[21]. The interaction of APP with the X11L mutants used in this
study was examined by coimmunoprecipitation (Fig. 2), which
reconfirmed that the PTB domain of X11L binds to APP as
described previously [1]. Although DPTB and F520V mutants had
an effect on imAPP accumulation and caused a decrease in CTFa
and CTFb (Fig. 1B and C), we confirmed that both mutants did
not associate with APP (Fig. 2, lanes 6 and 12). Therefore, we
concluded that the C-terminal region, which includes the PDZ
domains, is involved in the accumulation of imAPP, without being
bound to APP directly. This regulation by X11L in APP
metabolism, therefore, is independent of the suppression of
amyloidogenic cleavage of mAPP by X11L which is widely known
as X11s function in the regulation of APP metabolism [5,16,22].
The PTB+C mutant (Fig. 1B, lane 4; Fig. 1C, column 4)
strongly suppressed the maturation of APP compared to the C
mutant, which contained only the C-terminal region (Fig. 1B,
lane 10; Fig. 1C, column 10). Attachment of the N-terminal PTB
domain to the C region may have stabilized the conformation of
the C region included the two PDZ domains, because X11, a
member of X11 family proteins, is reported to form the closed
conformation of the PDZ domains [23]. The DPTB mutant,
possessing an intact C-terminal region also showed a weak activity
in imAPP accumulation (Fig. 1B, lane 6; Fig. 1C, column 6).
Lack of a central PTB domain may make difficult to preserve
functional C-terminal structure.
X11 and X11L2 expression also showed effects comparable to
those of X11L (Fig. 1B, lanes 13 and 14, and Fig. 1C, columns
13 and 14), regardless of their weaker binding to APP compared to
X11L (compare lane 3 with lanes 13 and 14 in Fig. 2, and see
Fig. S1 for confirmation of X11s binding to APP). This result
suggests that all members of X11s has ability to accumulate
imAPP and also supports that the association strength between
APP and the X11s is not involved in the accumulation of imAPP.
X11L mutants carrying the two PDZ domains but lacking APP-
binding ability also showed a significant decrease in the secretion
of both Ab40 and Ab42 derived from mAPP (Fig. 1D: C, column
10; F520V, column 12), as did entire X11s (X11L, column 3; X11,
column 13; X11L2, column 14) and X11L mutants containing
PTB domain (PTB+C, column 4; PTB, column11). In contrast to
these, DPDZ1 (column 7) did not suppress Ab generation and
DPDZ2 (column 8) showed very weak suppression of Ab40 alone.
The observations suggest that existence of both PDZ domains is
significant for the Ab suppression, which is thought to dependent
on the suppression of APP maturation. The DPTB mutant, in spite
of the preservation of intact PDZ domains, had no effect on Ab
suppression. This may reflect to a weak activity in imAPP
accumulation (Fig. 1C and D, column 6), as described above,
probably by the conformation of C-terminal structure. In contrast
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suppression of Ab generation without significant accumulation of
imAPP (Fig. 1C, column 11). This PTB fragment may be
relatively free to localize in cytoplasm and can associate
predominantly to mAPP (Fig. 2, lane 11), when compared to
other PTB containing X11L peptide (Fig. 2, lanes 4, 5, 7 and 8),
and is thought to suppress the amyloidogenic processing of mAPP
as described previously [16].
Figure 1. Suppression of APP maturation and proteolytic metabolism by the PDZ domains of X11 proteins. (A) Schematic
representation of the structures of amino-terminal tagged X11L proteins. a: human X11L, b: X11L-PTB+C (368 to 749), c: X11L-N+PTB (1 to 555), d:
X11L-DPTB (D369 to 555), e: X11L-DPDZ1 (D561 to 651), f: X11L-DPDZ2 (D661 to 749), g: X11L-N (1 to 368), h: X11L-C (556 to 749), i: X11L-PTB (369 to
555), j: X11L F520V, k: human X11, and l: human X11L2. PTB, phosphotyrosine binding domain; PDZ, PDZ domain. Oval indicates FLAG (Fig. 2) or EGFP
(Fig. 1, 3, 6) tag. Numbers indicate amino acid positions. (Bt oD ) Alteration of APP maturation and proteolytic metabolism in cells expressing EGFP-
X11L mutant proteins, X11 and X11L2. N2a cells (,2610
5) were transiently transfected with pcDNA3-FLAG-APP695 (0.8 mg) in the presence of various
X11L cDNA plasmids, pcDNA3.1-EGFP-X11L and pcDNA3.1-EGFP-X11L2 (a: 0.18 mg, b: 0.6 mg, c: 0.6 mg, d: 0.06 mg, e: 0.36 mg, f: 0.18 mg, g: 0.08 mg, h:
0.15 mg, i: 0.6 mg, j: 0.54 mg, k: 0.09 mg, and l: 0.12 mg). Plasmid amounts were adjusted to produce a similar level of protein expression, and empty
vector was added to yield a total of 1.4 mg of plasmid to standardize the amount of plasmid. The cell lysates were analyzed by immunoblotting with
an anti-FLAG M2 antibody to detect APP, an anti-EGFP antibody to detect X11L derivatives, an anti-actin antibody to detect actin, and an anti-APP/C
antibody to detect APP-CTFa/b (B). (C) The relative ratio of imAPP/mAPP is quantified. The relative ratio in cells in the absence of X11L was set as 1.0
(column 2). (D)A b40 and Ab42 secreted into the medium of N2a cells were quantified with sELISA. Concentrations of Ab40 (left) and Ab42 (right) are
shown as means 6 s.e. (n=4). Data were analyzed using the Student’s t-test (*, P,0.05; **, P,0.01; ***, P,0.001). Proteins showing a significant
decrease (P,0.01 and P,0.001) in Ab generation are shown as closed columns.
doi:10.1371/journal.pone.0022108.g001
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generation is composed of, at least, two functions; one is the
suppression of amyloidogenic processing of mAPP in late protein
secretory pathway [16] in which X11L binds to mAPP through the
PTB domain, and another is the regulation of APP maturation in
early protein secretary pathway, where the two PDZ domains of
X11L function to imAPP independent of the direct binding.
Appearance of imAPP on plasma membrane of cells
expressing X11s
Next, we explored the localization of imAPP accumulated in
cells expressing X11L. We considered that the imAPP dominantly
accumulated in ER and/or early Golgi as a matter of course.
Contrary to our expectations, we found that some of imAPP
accumulated in cells appeared on the plasma membrane without
O-glycosylation (Fig. 3A). Proteins exposed on the outer surface of
cells expressing FLAG-APP in the presence of various EGFP-
X11L proteins were biotinylated, recovered by NeutrAvidin beads
from cell lysates, and subjected to immunoblotting with an anti-
FLAG antibody. Usually only mAPP is detected on the plasma
membrane (Fig. 3A, lane 2) because imAPP is localized at the
early protein secretory pathway [11,19]. Nevertheless, imAPP was
detected on the plasma membrane of cells expressing X11L (lane
3), reproducibly. In this study, actin (cytoplasmic protein), calnexin
Figure 2. PTB domain-dependent binding of X11L to APP. N2a cells (,2610
5) were transiently transfected with pcDNA3-APP695 (0.6 mg) in
the presence of various cDNA plasmids encoding the FLAG-X11L proteins: FLAG-X11 and FLAG-X11L2 (a: 0.2 mg, b: 0.8 mg, c: 0.4 mg, d: 0.2 mg, e:
0.2 mg, f: 0.4 mg, g: 0.4 mg, h: 0.1 mg, i: 0.8 mg, j: 0.2 mg, k: 0.2 mg, and l: 0.2 mg). Plasmid amounts were adjusted to produce a similar level of protein
expression, and empty vector was added to yield 1.4 mg of plasmid in total to standardize the plasmid amount. The cell lysates were subjected to
immunoprecipitation with an anti-FLAG antibody. The immunoprecipitate (IP) and cell lysate were analyzed by immunoblot analysis with anti-FLAG
or anti-APP/C antibodies. Lanes a to l correspond to the protein constructs described in Figure 1A. Numbers indicate protein molecular weight
standards (kDa). Asterisks indicate non-specific, immuno-reaction products. Association of X11s with APP is also shown in Figure S1.
doi:10.1371/journal.pone.0022108.g002
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cell-surface samples (Fig. S2), indicating that only cell-surface
proteins were biotinylated.
Cell surface-localized imAPP was also observed in cells
expressing the PTB+C mutant (Fig. 3A, lane 4), and a moderate
level of imAPP was detected on the surface of cells expressing C
(Fig. 3A, lane 10) and F520V (lane 12). The mutants lacking
either or both PDZ domains (N+PTB, lane 5; DPDZ1, lane 7;
DPDZ2, lane 8; N, lane 9; PTB, lane 11) had no effect on the
presence of imAPP on the plasma membrane. One mutant DPTB,
possessing an intact C-terminal region, also had no effect (lane 6)
which may be due to a weak activity in imAPP accumulation
(Fig. 1B, lane 6; Fig. 1C, column 6; Fig. 3A, lane 6 of second
row). These observations suggested that some of imAPP
accumulated by expression of X11L proteins containing C-
terminal PDZ domains was transported to plasma membrane
and this activity might tend to be enhanced in the presence of
entire PTB domain (compare lane 4 to lane10, and compare lane
3 to lane 12 in Fig. 3A).
The observation that imAPP exposed on the plasma membrane
of cells that expressed with X11L implies that imAPP, which was
not subjected to O-glycosylation, might be transported to the
plasma membrane by unidentified mechanism, probably differs
from the classical Golgi mediated protein secretory pathway. To
Figure 3. Cell surface expression of imAPP induced by X11L mutant proteins. (A) Effect of X11L mutant proteins. N2a cells (,2610
5) were
transiently transfected with pcDNA3-FLAG-APP (0.8 mg) in the presence of various cDNA plasmids encoding EGFP-X11L proteins (a: 0.18 mg, b: 0.6 mg,
c: 0.6 mg, d: 0.06 mg, e: 0.36 mg, f: 0.18 mg, g: 0.08 mg, h: 0.15 mg, i: 0.6 mg, and j: 0.54 mg). To standardize the plasmid amount, empty vector was added
to yield 1.4 mg of plasmid in total. Cells were labeled with sulfo-NHS-LC-biotin and NeutrAvidin was used to collect the biotinylated proteins. The cell
lysates and biotinylated proteins (Cell surface) were analyzed by immunoblotting with an anti-FLAG antibody to detect APP, an anti-EGFP antibody to
detect X11L proteins, and an anti-actin antibody to detect actin. Lanes a to j correspond to the constructs described in Figure 1A. (B) Specificity of
X11s function. N2a cells (,2610
5) were transiently cotransfected with pcDNA3-FLAG-APP695 (0.6 mg) and 0.2 mg of the following plasmids:
pcDNA3.1-HA-X11 (lane 3), pcDNA3.1-HA-X11L (lane 4), pcDNA3.1-HA-X11L2 (lane 5), pcDNA3.1-HA-FE65 (lane 6), or pcDNA3.1-HA-JIP1b (lane 7).
Cells were labeled with sulfo-NHS-LC-biotin and NeutrAvidin was used to collect biotinylated proteins. The cell lysate and biotinylated proteins (Cell
surface) were analyzed by immunoblotting with an anti-FLAG antibody to detect APP, an anti-HA antibody to detect HA-binding proteins, and an
anti-actin antibody to detect actin.
doi:10.1371/journal.pone.0022108.g003
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ation in the Golgi, we examined the expression of the vesicular
stomatitis virus G protein (VSVG), a protein subjected to O-
glycosylation [24], and found that O-glycosylated VSVG was
detected in cells in the presence, and absence, of X11L expression
(Fig. S3). Although we cannot rule out a possibility that the
presence of X11L may specifically interfere with the O-
glycosylation of imAPP without affecting the O-glycosylation of
VSVG, this result supports our observation that imAPP was
transported to the plasma membrane, by unidentified way,
probably without passing Golgi mediated protein secretory
pathway.
To reconfirm that protein mobility shift on SDS-PAGE is due to
the O-glycosylation of APP (this has been demonstrated in our and
others’ previous works [10,19,25]) , APP was recovered from cells
with or without X11L expression, after cell surface labeling of
proteins with biotin, by immunoprecipitation with anti-APP
antibody (Fig. S4). The immunoprecipitated APP was treated
with endoglycosidase H to remove N-glycans, neuraminidase to
remove neuraminic acids, and a combination of neuraminidase
and O-glycanase (O-glycans with terminal neuraminic acid show
resistance to O-glycanase) to remove O-glycans [10], and APP
exposed on the outer surface of cells was detected by immuno-
blotting with anti-biotin antibody. The outer surface-localized
mAPP of cells without X11L expression moved down to the
position of imAPP on SDS-PAGE (Fig. S4, left), indicating that O-
glycans were removed from mAPP. In contrast to this, the outer
surface-localized imAPP of cells with X11L expression did not
show the mobility shift by enzyme treatment (Fig. S4, right),
indicating that imAPP, which is not subject to O-glycosylation,
appeared to the outer surface of cells in the presence of X11L.
This effect is characteristic of X11 family proteins. Other APP-
binding proteins, such as FE65 and JIP1b which are also recognize
the 681-GYENPTY-687 motif in the APP cytoplasmic region
[19,20], did not accumulate imAPP in cells and appear imAPP on
the plasma membrane (Fig. 3B).
We further and carefully performed studies to verify the
transport of imAPP. It is known that the reduced temperature
prevents transfer of membrane glycoproteins to cell surface
[26,27]. Cells with or without expression of X11L were cultured
at 20uC for 0 to 12 h and APP exposed on the outer surface of cells
was analyzed by immunoblotting along with total cellular APP
(Fig. 4). In the absence of X11L expression, cell surface-localized
mAPP decreased depending on culture time and no surface mAPP
was detected at 8 h (Fig. 4A, lanes 3 to 7), while in the presence of
X11L, cell surface-localized imAPP first decreased by 2–4 h but
re-increased at 8 to 12 h (Fig. 4A, lanes 8 to 12). The quantitative
analysis of APP exposed on the outer surface of cells was also
shown in Fig 4 B (left, mAPP on cell surface of cells without X11L
expression; right, imAPP on cell surface of cells with X11L
expression). This study supports our idea that X11L mediates
imAPP transfer onto plasma membrane by unidentified mecha-
nism but not through the conventional Golgi mediated secretory
pathway.
Rab1 is known as an essential factor required for the ER to
Golgi transport [28]. We analyzed the transport of APP from the
ER to the plasma membrane using dominant-negative mutants of
Rab1a and Rab1b. We explored four dominant-negative mutants,
Rab1aS25N (Asn was substituted for Ser25 of Rab1a), Ra-
b1aN124I (Ile was substituted for Asn124), Rab1bS22N (Asn was
substituted for Ser 22 of Rab1b) and Rab1bN121I (Ile was
substituted for Asn121) in the effect of the accumulation of imAPP
(Fig. S5). As expected, these dominant-negative Rab1 mutants
inhibited the maturation of APP and accumulated imAPP in cells.
Because Rab1bN121I mutant was most effective to accumulate
imAPP, we further examined whether X11L expression performs
the cell surface transport of imAPP which was accumulated in the
ER by the expression of Rab1bN121I mutant (Fig. 5). In the
absence of X11L, mAPP alone appeared on cell surface and the
amount was decreased by the expression of Rab1bN121I mutant
(Fig. 5, compare lane 2 to lane 4 on first row). The expression of
Rab1bN121I increased intracellular imAPP (compare lane 4 to
lane 2 on second row) but the imAPP did not appear on cell
surface (lane 4 on first row). When X11L was expressed with
Rab1bN121I, imAPP appeared on the cell surface (lane 5 on first
row) along with accumulated intracellular imAPP (lane 5 on
second row), indicating that imAPP accumulated in ER under the
expression of dominant-negative mutant of Rab1b was transferred
to the plasma membrane without passing Rab1b-dependent
classical secretory pathway. Taken together, X11L can mediate
the transport of imAPP to the plasma membrane by unidentified
mechanism, which is different from Golgi mediated protein
secretory pathway.
The localization of FLAG-APP in cells expressing X11L and
the PTB+C mutant was compared in cells with, or without,
permeabilization. Cells expressing X11L and PTB+C showed
localization of APP to the plasma membrane when cells were not
permeabilized as observed in cells without expression of X11L
(Fig. 6, left [intact cell]; vector, no expression of X11L),
regardless of the fact that almost no mAPP was found in cells
expressing X11L and PTB+C( Fig. 3A, lanes 3 and 4). No
intracellular-staining of FLAG-APP was observed in intact cells.
In contrast to this, FLAG-APP was detected both at perinuclear
region and to plasma membrane of permeabilized cells (Fig. 6,
right [permeabilized cell]. This result confirmed that the
periplasmic staining of FLAG-APP observed in intact cells was
due to signal of imAPP present on the cell surface (Fig. 3A). The
imAPP exposed on the plasma membrane may be not a result of
membrane fusion between the ER and the plasma membrane in
response to X11L expression or an observation of ER membrane
fragments, because the ER-resident transmembrane protein,
calnexin, was not detected on the plasma membrane of cells
expressing X11L (Fig. S2). These results (Fig. 6), together with
the biochemical analyses (Figs. 3 to 5), supported our idea that
X11L has the ability to transport imAPP, which was accumulated
in the early secretory pathway such as ER, to the plasma
membrane.
To confirm furthermore that this unidentified pathway that was
capable of transporting imAPP to the plasma membrane was not
an artificial event due to the exogenous expression of X11L, we
explored whether cells also utilized this pathway when APP
maturation was suppressed, without the exogenous expression of
X11L. Treatment of cells with brefeldin A (BFA) inhibits the
transport of secretory/membrane proteins from the ER to the
Golgi. In fact, cells treated with BFA showed a remarkable
increase in imAPP at 2 hr (Fig. 7, lane 5 in second row), and
mAPP completely disappeared from the cell surface at 2 h (Fig. 7,
lane 5 in first row). Interestingly, imAPP appeared on the outer cell
surface at 8 h of BFA treatment (lane 7 in first row), which was
weak but similar to cells expressing X11L (lane 8 in first row).
These observations indicated that cells may naturally possess a
secretory pathway that transports imAPP from the ER to the
plasma membrane; however, this unidentified pathway may be
generally quiescent. When the Golgi mediated protein secretory
pathway is subject to malfunction, this pathway, in which X11s is
expected to play an important role, may help to dispose of some of
the accumulated protein(s). Indeed, in Fig. 7, endogenous X11
proteins, including the ubiquitously expressed X11L2, may
Intracellular Regulation of APP by X11L
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without the exogenous expression of X11L.
Discussion
The X11 family proteins X11, X11L and X11L2 are adaptor
proteins, which contain a divergent N-terminal region that binds
synaptic proteins such as Munc-18 and an evolutionarily
conserved C-terminal region with a phosphotyrosine binding/
phosphotyrosine interaction (PTB/PI) domain that associates
with various proteins such as APP, Alcadein and ADP-
ribosylation factor (Arf) and two PDZ domains that interact with
proteins such as KIF17 and NF-kB [1,29–34]. Cell activities such
as intracellular protein transport, presynaptic neurotransmitter
release and protein metabolism are regulated through protein-
protein interactions mediated by members of the X11 family
[5,20,35].
In this study, we have focused on the novel role of X11s in the
intracellular transport of APP, because Ab, which is a major factor
in the pathogenesis of Alzheimer’s disease [12], is generated from
the proteolytic cleavages of APP during protein secretory pathway
[11]. Among the X11 proteins, X11L binds more strongly to APP
than either X11 or X11L2 (Fig. 2 and Fig. S1), and in brain,
X11L is expressed more widely than X11, and colocalizes with the
expression of APP [16]. Furthermore, X11L-deficient mice
showed a remarkable increase in the amyloidogenic processing
of endogenous mAPP, including Ab generation, in the brain
compared to X11-deficient mice, which indicated that X11L
contributes to the regulation of APP metabolism along with the
protein transport in cells to a greater extent than does X11
[15,16].
At least two independent mechanisms are possible in the
suppression of APP metabolism by X11s. One of the mechanisms
through which X11s regulate APP metabolism is the suppression
Figure 4. Cell surface appearance of imAPP by X11L expression in cells suffered from reduced temperature. N2a cells (,1610
6)
transferred transiently with 0.6 mg of pcDNA3-FLAG-APP with (+) or without (2) 0.2 mg of pcDNA3.1-HA-X11L were cultured for indicated time (h) at
20uC. To standardize the plasmid amount, empty vector was added to yield 0.8 mg of plasmid in total. The cells were labeled with sulfo-NHS-LC-biotin
and NeutrAvidin was used to collect biotinylated proteins. (A) The cell lysates and biotinylated proteins (Cell surface) were subjected to immunoblot
analysis with anti-FLAG antibody to detect APP, anti-HA antibody to detect X11L, and anti-a-tubulin antibody to detect a tubulin. (B) The relative
ratio of cell surface mAPP in cells without X11L expression (first row of left panel; lanes 3 to 7 in A) and that of cell surface imAPP in cells with X11L
expression (first row of right panel; lanes 8 to 12 in A) are quantified. The relative ratio in cells at time 0 (lanes 3 and 8) was set as 1.0. Data were
analyzed using the Student’s t-test with standard error (n=4; *, P,0.05).
doi:10.1371/journal.pone.0022108.g004
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region (DRM) or lipid raft, where b-secretase is active, by the
direct binding of X11s to mAPP. This direct binding by X11s
suppresses the amyloidogenic cleavage of APP by b-secretase
[16,22,35]. X11s also bind to c-secretase and directly suppress the
c-site cleavage of mAPP [36,37]. In either situation, the metabolic
suppression of mAPP by direct binding to X11s occurs during the
late protein secretory pathway. In addition to the suppression of
mAPP cleavages, X11s expression in cells induces an overall
metabolic stabilization of APP, in other words, X11s induce
intracellular accumulation of imAPP, which leads to a consequent
decrease in Ab generation, but the detailed mechanism was still
unclear [1,6–9] when compared to X11L function to prevent
amyloidogenic cleavage of mAPP [16,22].
In this study, we analyzed the mechanism of imAPP accumu-
lation in cells with expression of X11L. Our results revealed that
the C-terminal PDZ domains of X11L are required for the
suppression of APP maturation and the accumulation of imAPP;
however, the PTB/PI domain, required for APP-binding, was
independent of this activity. Although the molecular mechanism
by which X11L suppresses the maturation of imAPP is still under
consideration, X11s may be a component to regulate protein
transport between early and late Golgi, or the ER and early Golgi.
Another APP-binding protein Numb was reported to accumu-
late mAPP, but not imAPP, into the early endosomal and recycling
compartments of cells [38]. The orchestrated functions of such
adaptor proteins to APP in the respective stages of protein
secretory pathway may play an important role in the intracellular
transport and metabolism of APP.
We found that some of imAPP accumulated in the early
secretory pathway by expression of X11L appeared on the cell
surface plasma membrane without O-glycosylation. The C-
terminal PDZ domains of X11L were required for this activity.
Although the presence of the PTB/PI domain along with the PDZ
domains seemed to enhance the appearance of imAPP on the
plasma membrane, the interaction of imAPP with X11L via the
PTB/PI domain is not involved in the imAPP transport. This
imAPP transport to the plasma membrane was verified by three
independent procedures; (i) when cells were cultured at 20uC
which blocks the secretoty pathway at the late Golgi, cellular
imAPP accumulated and the imAPP was appeared on the plasma
membrane in the presence of X11L, (ii) when Rab1 dominant-
negative mutant which blocks the transport of proteins from the
ER to the Golgi were expressed in cells, the accumulated
intracellular imAPP appeared on the plasma membrane by
expression of X11L, and (iii) when brefeldin A blocked the
transport of proteins from the ER to the Golgi, imAPP appeared
on plasma membrane in cells, without exogenous expression of
X11L.
Taken together, excess X11s suppress the maturation of APP by
preventing the imAPP transport into the late secretory pathway,
but X11s also show their function to transport the imAPP
accumulated in the early secretory pathway to the plasma
membrane. Cells are likely to possess this unidentified pathway
to transport proteins accumulated in the ER to the plasma
membrane, as can be observed in a study with BFA (Fig. 7), which
may be mediated by X11s, but this pathway must be very slender
when classical Golgi-mediated pathway has functioned in healthy
cells.
The idea that other membrane and secretory proteins, which
are not involved in APP or X11s, may be transported to the
plasma membrane from the ER, when proteins are accumulated
Figure 5. Cell surface appearance of imAPP by X11L expression
in cells expressing Rab1b dominat-negative mutant. N2a cells
(,2610
5) were transferred transiently with 0.3 mg of pcDNA3-FLAG-APP
with (+) or without (2) 0.1 mg of pcDNA3.1-HA-X11L and 0.4 mg of pCA-
FLAG-Rab1bN121I. To standardize the plasmid amount, empty vector
was added to yield 0.8 mg of plasmid in total. The cells were labeled
with sulfo-NHS-LC-biotin and NeutrAvidin was used to collect
biotinylated proteins. The cell lysates and biotinylated proteins (Cell
surface) were subjected to immunoblot analysis with anti-FLAG
antibody to detect APP, anti-HA antibody to detect X11s, and anti-a-
tubulin antibody to detect a tubulin.
doi:10.1371/journal.pone.0022108.g005
Figure 6. Expression of APP on the outer membrane. N2a cells (,2610
4) were transiently cotransfected with 0.1 mg of pcDNA3-FLAG-APP695
and 0.04 mg of pcDNA3.1-EGFP-X11L, pcDNA3.1-EGFP-PTB+C, or empty vector. The cells were washed with ice-cold PBS, and FLAG-APP present on
the cell surface was labeled with anti-FLAG antibody and anti-mouse IgG antibody-conjugated Alexa 546 on ice (Intact cell, left panels). The same
intact cells were permeabilized and intracellular APP was detected with anti-APP/C antibody and anti-rabbit IgG antibody-conjugated Alexa 633
(Permeabilized cell, right panels). The cells were observed using a confocal laser-scanning microscope LSM510 (Carl Zeiss, Oberkochen, Germany).
DIC: Differential Interference Contrast microscopy; DNA: nuclear DNA staining with 49,6-diamino-2-phenylindole (DAPI). Signals are merged in the
right-hand rows. Scale bar, 5 mm.
doi:10.1371/journal.pone.0022108.g006
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APP works as a vesicular cargo receptors for the motor protein
kinesin-1 [39,40] Therefore, APP vesicles may contain various
types of membrane-associated and/or secretory proteins. Thus,
such proteins may also be transported to the plasma membrane
when the proteins are unusually accumulated in the early secretory
pathway.
In any case, our observations suggest that the existence of an
unidentified protein trafficking pathway at least for APP, in which
X11s are likely to involve in the regulation of imAPP accumulation
and transport. Such novel X11s function, together with the known
X11s function of the regulation of APP processing by directly
binding to APP, controls APP metabolism through the regulation
of APP trafficking. Therefore, understanding for both roles of
X11s in APP metabolism and transport should shed light on the
molecular mechanism of Ab generation in Alzheimer’s disease.
Materials and Methods
Plasmids
The cDNA constructs pcDNA3-APP695, pcDNA3-FLAG-AP-
P695, pcDNA3.1-FLAG-X11L, pcDNA3.1-FLAG-X11L-PTB+C,
pcDNA3.1-FLAG-X11L-N+PTB, pcDNA3.1-FLAG-X11L F520V
(Phe to Val mutation at amino acid 520), pcDfNA3.1-HA-X11L,
pcDNA3.1-HA-X11, pcDNA3.1-HA-X11L2, pcDNA3.1-HA-FE-
65, pcDNA3.1-HA-JIP1b, pcDNA3.1-EGFP-X11L, pcDNA3.1-
EGFP-X11, and pcDNA3.1-EGFP-X11L2 have been described
previously [1,21,41–44]. The constructs, pcDNA3.1-FLAG-X11L-
DPTB (deletion of amino acids 369 to 555), pcDNA3.1-FLAG-
X11L-DPDZ1 (deletion of amino acids 561 to 651), pcDNA3.1-
FLAG-X11L-DPDZ2 (deletion of amino acids 661 to 749),
pcDNA3.1-FLAG-X11L-N (amino-terminal amino acids 1 to 368),
pcDNA3.1-FLAG-X11L-C (carboxyl-terminal amino acids 556 to
749), and pcDNA3.1-FLAG-X11L-PTB (amino acids 369 to 555)
were generated by PCR using pcDNA3.1-FLAG-X11L as the
template. The fragments generated were then ligated into pcD-
NA3.1-FLAG-X11L at the NheI/XhoI site instead of the X11L
sequence.TheconstructspcDNA3.1-EGFP-X11L-PTB+C, pcDNA-
3.1-EGFP-X11L-N+PTB, pcDNA3.1-EGFP-X11L F520V, pcDN-
A3.1-EGFP-X11L-DPTB, pcDNA3.1-EGFP-X11L-DPDZ1, pcDN-
A3.1-EGFP-X11L-DPDZ2, pcDNA3.1-EGFP-X11L-N, pcDNA-
3.1-EGFP-X11L-C, and pcDNA3.1-FLAG-X11L-PTB were gener-
ated by replacing the FLAG-tag with EGFP. The construct pcD-
NA3.1-VSV-G-ts045-GFP was kindly gifted from Dr. J. Lippin-
cott-Schwartz [24]. The constructs pCA-FLAG-Rab1aN124I, pCA-
FLAG-Rab1aS25N, pCA-FLAG-Rab1bN121I and pCA-FLAG-
Rab1bS22N were kindly gifted from D. Y. Kawaoka [45].
Antibodies
The commercially available antibodies used in this study were
purchased as follows: mouse monoclonal anti-FLAG antibody (M2,
Sigma-Aldrich, St Louis, MO, USA), anti-HA (12CA5, Roche
Diagnostics, Mannheim, Germany), anti-GFP (1E4, Medical &
Biological Laboratories/MBL, Nagoya, Japan), anti-GM130 and
anti-syntaxin 6 (BD Biosciences, Franklin Lakes, NJ, USA), anti-
actin (MAB1501, Chemicon/Millipore, Billeria, MA, USA), anti-a-
tubulin (sc-32293, SANTA CRUZ Biotech., Santa Cruz CA, USA)
and anti-Ab (82E1, Immuno-Biological Laboratories/IBL, Fujioka,
Japan); rabbit polyclonal anti-APP C-terminal APP/C (A8717,
Sigma-Aldrich), and anti-calnexin (Stressgen, Ann Arbor, MI,
USA); goat polyclonal anti-rabbit and anti-mouse immunoglobulin
antibodies conjugated to horseradish peroxidase (GE Healthcare
Life Sciences, Little Chalfont, UK); and goat anti-rabbit and horse
anti-mouse immunoglobulin antibodies conjugated to Alexa 546 or
Alexa 633 (Molecular probes/Invitrogen, Carsbad, CA, USA).
Cell culture and expression of proteins
Mouse neuroblastoma cell line Neuro2a (N2a) cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS). To express proteins, approximately (,)2 610
5 cells for a
12-well dish and ,1610
6 cells for a six-well dish were transiently
transfected with 0.3 to 1 mg of the plasmids indicated using
LipofectAMINE 2000 (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s protocol. The cells were cultured for 32
to 36 h in DMEM containing 10% (v/v) FBS.
Quantification of Ab40 and Ab42
N2a cells (,1610
6) were transiently transfected with pcDNA3-
FLAG-APP695 and the plasmid indicated, and then cultured for 32
to 48 h. Ab40 and Ab42, secreted into the medium,werequantified
using a sandwich enzyme-linked immunosorbent assay (sELISA) as
described previously [46]. Briefly, the wells of a 96-well plate were
coated with Ab40 (4D1) or Ab42 (4D8) end-specific monoclonal
antibodies (0.3 mg of IgG in PBS), washed with PBS containing
0.05% (v/v) Tween 20 (PBST), blocked with bovine serum albumin
(BSA, 3% [w/v] in PBS), and washed with PBST [10]. Then, a
sample (100 ml), suitably diluted with PBST containing 1% (w/v)
BSA (dilution buffer), was incubated together with a standard
amount of synthetic Ab1-40 or Ab1-42 peptide. After washing, the
wells were treated with biotinylated 82E1 [47], washed, and
incubated with 100 ml of a streptavidin-horseradish peroxidase
complex (1:2,000 dilution; RPN1051, Amersham Pharmacia
Biotech). The plates were washed again, and 100 ml of 2,29-azino-
bis (3-ethylbenzothiazoline-6-sulfonia acid) or ABTS solution (KPL
5062-01, Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD)
was added to the wells. The plates were incubated at room
temperature and the absorbance was measured at 415 nm.
Co-immunoprecipitation and biotinylation of cell surface
proteins
N2a cells (,1610
6) were transiently transfected with the
plasmid indicated as described above. Cells were harvested and
Figure 7. imAPP transport to plasma membrane in cells treated
with Brefeldin A. N2a cells (,2610
5) were transiently transfected
with pcDNA3.1-FLAG-APP (0.6 mg) in the presence (lane 8) or absence
(lanes 3 to 7) of pcDNA3.1-HA-X11L (0.2 mg). To standardize the plasmid
amount, empty vector was added to yield 0.8 mg of plasmid in total.
Cells were treated with brefeldin A (BFA, 10 mg/ml) for 10 min (1/6 h,
lane 4), 2 h (lane 5), 4 h (lane 6) and 8 h (lanes 2 and 7), or without
reagent (2, lanes 1, 3, 8). Cells were labeled with sulfo-NHS-LC-biotin
and NeutrAvidin was used to collect the biotinylated proteins (Cell
surface). The cell lysates and biotinylated proteins were subjected to
immunoblot analysis with anti-FLAG antibody to detect APP, anti-HA
antibody to detect X11L, and anti-actin antibody to detect actin.
doi:10.1371/journal.pone.0022108.g007
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150 mM NaCl, 5 mM EDTA, 0.5% [v/v] Triton X-100, 5 mg/ml
chymostatin, 5 mg/ml leupeptin, and 5 mg/ml pepstatin A) and
centrifuged at 10,0006g for 10 min. The resulting supernatants
were incubated with the antibodies indicated at 4uC for 2 h. The
immunocomplex was recovered using protein G-Sepharose beads
(GE Healthcare Life Sciences), and the proteins were analyzed by
immunoblotting with the antibodies indicated.
Cell surface proteins were biotinylated with EZ-Link Sulfo-
NHS-LC-Biotin (Thermo Fisher Scientific, Walthan, MA USA)
for 30 min on ice, and the reaction was stopped by washing cells
with PBS containing 50 mM glycine. The cells were lysed in HBS-
T, and biotinylated proteins were recovered with Immobilized
NeutrAvidin Gel (Thermo Scientific) and analyzed by immuno-
blotting. Actin and calnexin were used as controls to show that the
intracellular proteins were not biotinylated.
Brefeldin A treatment
N2a cells (,1610
6) were transiently transfected with the
amount of plasmid indicated as described above and treated with
10 mg/ml of brefeldin A (BFA, Sigma-Aldrich) for 10 minutes, and
two, four, or eight hours. Cell surface proteins were biotinylated
with EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) for
30 min on ice, and the reaction was stopped by washing cells
with PBS containing 50 mM glycine [48]. The cells were lysed in
HBS-T, and biotinylated proteins were recovered and analyzed by
immunoblotting as described above.
Supporting Information
Figure S1 Binding ability of X11 proteins to APP. N2a
cells (,2610
5) were transiently transfected with pcDNA3-
FLAG-APP695 (0.6 mg) in the presence (+,0 . 2mg) or absence
(2) of pcDNA3.1-HA-X11, pcDNA3.1-HA-X11L and pc
DNA3.1-HA-X11L2. To standardize the plasmid amount,
empty vector was added to yield 0.8 mg of plasmid in total.
The cell lysates were subject to co-immunoprecipitation with
anti-FLAG antibody. The immunoprecipitate (IP) and cell
lysates were subjected to immunoblot analysis with anti-HA
and anti-FLAG antibodies.
(TIFF)
Figure S2 Specific labeling of cell surface proteins. N2a
cells (,2610
5) were transiently transfected with pcDNA3-FLAG-
APP695 (0.6 mg) in the presence (+) or absence (2) of pcDNA3.1-
EGFP-X11L (0.2 mg). To standardize the plasmid amount, empty
vector was added to yield 0.8 mg of plasmid in total. Cells were
labeled with sulfo-NHS-LC-biotin and NeutrAvidin was used to
collect biotinylated proteins. The cell lysates and biotinylated
proteins (Cell surface) were subjected to immunoblot analysis with
an anti-FLAG antibody to detect APP, an anti-EGFP antibody to
detect X11L, an anti-calnexin antibody to detect calnexin, and an
anti-actin antibody to detect actin.
(TIFF)
Figure S3 Suppression of O-glycosylation of APP, but
not VSVG, by X11L. (A) N2a cells (,2610
5) were transiently
transfected with pcDNA3-FLAG-APP695 (0.4 mg) in the presence
(+) or absence (2) of pcDNA3.1-HA-X11L (0.4 mg). To
standardize the plasmid amounts, empty vector was added to
yield 0.8 mg of plasmid in total. The cell lysates were analyzed by
immunoblotting with an anti-FLAG (M2) antibody to detect APP
and an anti-HA antibody to detect X11L. (B) N2a cells (,2610
5)
cultured at 32uC or 39.5uC were transiently cotransfected with
pcDNA3.1-VSVG-ts045-GFP (0.4 mg) and pcDNA3.1-HA-X11L
(0.4 mg) or empty vector (2). The cell lysates were analyzed by
immunoblotting with an anti-EGFP antibody to detect VSVG-
ts045-GFP and an anti-HA antibody to detect X11L. This
temperature sensitive (ts) mutant of the VSVG protein resides in
the early secretary pathway at 32uC and is transported into the late
secretary pathway where O-glycosylation occurs at 39.5uC. The
‘‘mature’’ indicates proteins modified with O-glycosylation.
(TIFF)
Figure S4 Characterization of APP exposed on the outer
surface of cells. HEK293 cells were (,1610
6) were transferred
transiently with 0.5 mg of pcDNA3-FLAG-APP with (right panel)
or without (left panel) pcDNA3-hX11L (Tomita et al., [1999] J.
Biol. Chem. 274, 2243–2254). The cell surface proteins were
biotynylated and cells were lysed as described in text. Biotinylated
APP were treated with the enzymes indicated as descrived
previously (Tomita et al., [1998] J. Biol. Chem. 273, 6277–6284)
and recovered by immunoprecipitation with anti-APP G369
antibody (Oishi et al., [1997] Mol. Med. 3, 111–123) and the
immunoprecipitates were analyzed by immunoblotting with anti-
biotin antibody (BN-34, AbcamCambridge, UK). Control,
samples treated without enzyme (buffer alone),; Endo H, samples
treated with endoglycosidase H; Neu, samples treated with
neuraminidase; Neu+O-Gly, samples treated with a combination
of neuraminidase and O-glycanase. mAPP, mature APP (N- and
O-glycosylated APP); imAPP, immature APP (N-glycosylated
APP).
(TIFF)
Figure S5 Effect of Rab1 dominant-negative forms in
intracellular accumulation of imAPP. N2a cells (,2610
5)
were transferred transiently with 0.3 mg of pcDNA3-FLAG-APP
with or without (2) 0.3 mg of pCA-FLAG-Rab1aS25N (lane 3),
0.4 mg of pCA-FLAG-Rab1aN124I (lane 4), 0.3 mg of pCA-
FLAG-Rab1bS22N (lane 5) or 0.4 mg of pCA-FLAG-Rab1b-
N121I (lane 6). To standardize the plasmid amount, empty vector
was added to yield 0.7 mg of plasmid in total. The cell lysates were
subjected to immunoblot analysis with anti-FLAG antibody to
detect APP and rab1, and anti-a-tubulin antibody to detect a
tubulin. mAPP, mature APP (N- and O-glycosylated APP); imAPP,
immature APP (N-glycosylated APP).
(TIFF)
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